ABSTRACT
The endothelium provides a selective nonthrombogenic interface between blood and tissue. Endothelial cells possess highly specialized metabolic properties and respond to a variety of exogenous stimuli (1, 2) . The endothelium also plays a central role in physiological processes such as tissue regeneration and luteinization and in pathological states such as tumor angiogenesis, thrombotic events, and atherosclerosis (1, 2) . The survival, differentiation, and proliferation of a variety of cell types are mediated by polypeptide growth factors (3, 4) . Clearly, the endothelium is also influenced by a variety of biological response modifiers that induce their migration and proliferation. Mechanistic studies of endothelial cell biology have been prompted by the establishment of in vitro culture conditions (5, 6) , the definition of endothelial cell phenotypes (7, 8) , and the identification of polypeptide growth factors that interact with endothelial cells (9, 10) .
Bovine neural tissue contains several polypeptide mitogens for mesenchymal cells, including fibroblast growth factor (FGF), a cationic polypeptide that has been purified from bovine pituitary (11) and brain (12) . FGF has been extensively studied by Gospodarowicz and colleagues as a mitogen and survival factor for endothelial cells in vitro, in particular of bovine origin (13) . Biochemically distinct from FGF is endothelial cell growth factor (ECGF), an anionic polypeptide purified from bovine neural tissue (14, 15) . ECGF is the principal mitogen in bovine neural tissue for human endothelial cells (15) and permits the serial propagation of human endothelial cells in vitro (1, 8, (16) (17) (18) . It has recently been demonstrated that the anionic glycosaminoglycan heparin potentiates the mitogenic activity of crude preparations of ECGF (18) and structurally interacts with the anionic polypeptide ECGF (15) . In this report we expand these observations and demonstrate that heparin alters immunological epitopes within the structure of ECGF and increases the affinity of ECGF for its cell surface receptor. These data suggest that the potentiation of the biological activity of ECGF by heparin involves the stabilization of the tertiary structure of the polypeptide.
MATERIALS AND METHODS
Cells and Reagents. Human epidermoid carcinoma (A-431), human alveolar carcinoma (A-549), and BALB/c 3T3 murine cells were kindly provided by G. Todaro. Murine (AKR/J) lung capillary endothelial cells, LE-II, were the generous gift of A. Curtis. Human foreskin fibroblasts (HFF) and endothelial cells from human umbilical vein (HUVEC), bovine aorta (BAEC), bovine pulmonary vein (BPEC), and rabbit aorta (RAEC) were established from primary cultures. All cells were maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). HUVEC, BAEC, BPEC, and RAEC were grown on fibronectin-coated dishes (10) with crude ECGF at 50 ,ug/ml. Purified epidermal growth factor (EGF) and FGF were generous gifts of D. Gospodarowicz. Human platelet-derived growth factor (PDGF; receptor grade) was purchased from Collaborative Research; bovine insulin and growth hormone, from Sigma; and heparin, from Abbott, Upjohn, Sigma, Armour, and Eli Lilly. Heparin-Sepharose 6B was purchased from Pharmacia. lodination of ECGF. ECGF was purified to apparent homogeneity by procedures previously described, with rhinor modifications (14, 15) . Preparations of purified ECGF (single-chain polypeptide, Mr approximately 20,000) were biologically active in the range of 250-400 pg/ml and were judged to be greater than 90% pure by NaDodSO4/PAGE followed by silver staining. The polypeptide (2 Preparation of Antibodies to ECGF. Murine monoclonal antibodies against ECGF were prepared and characterized as previously described (15) . Polyclonal antiserum against ECGF was prepared in rabbits according to Lerner (19 (Fig. 3) from 5 x 10-11 M to 10-11 M. The potentiation of ECGF biological activity by heparin was also concentration dependent, with half-maximal potentiation occurring at approximately 10 ,ug/ml (Fig.  3 Inset). All data were obtained with heparin from either Upjohn or Armour. Heparin from other suppliers yielded qualitatively similar results. The biological activity of ECGF is labile to extreme perturbation of temperature and pH (1, 9) . Although purified ECGF can be stored at -200C in 10% glycerol containing 50 mM Tris HCl at pH 7.5 and 150 mM NaCl for 1-2 months, the biological activity decays rapidly after 6 months (Fig. 4) . However, approximately 80% of the original biological potency lost upon storage can be regained by adsorption of the "denatured" ECGF preparation to immobilized heparin, with a recovery of approximately 70% of the total protein. (Fig. SB) . These data demonstrate that the mitogenic activity of ECGF occurs as a result of the polypeptide binding to its -eceptor and is not due to a minor contaminant in the preparation. we questioned whether heparin influenced epitope exposure of ECGF to antibodies. A double antibody assay was designed since (i) the H9, H18, and H22 antibodies were IgM, (ii) the IgM monoclonal antibodies were unstable and did not adsorb well onto solid phases, and (iii) the IgG1 monoclonal antibody H15 possessed a low affinity for ECGF (Kd = 10-7 M). For the assay, ECGF was allowed to bind to solid phase-adsorbed polyclonal anti-ECGF IgG, and the effect of heparin on the subsequent binding of the monoclonal antibodies was quantitated. We observed that heparin significantly improved the affinity of H9 and H15 monoclonal antibodies for ECGF without an alteration of the maximal amount of antibody bound (Fig. 5C) biosynthesis and storage and to probe the potential similarity with other endothelial cell mitogens such as "acidic" FGF (21, 22) and eye-derived growth factor (23) . In preliminary experiments, we were unable to immunologically detect significant levels of ECGF in normal human serum and urine.
Heparin and other glycosaminoglycans affect cellular behavior in many systems, including the blood vessel wall (1) . Whereas heparin appears to inhibit proliferation of smooth muscle cells (24) , it also enhances the migration of capillary endothelial cells (25) . Mast cells are present at the leading edge of developing blood vessels (26) , and heparin stimulates neovascularization (27) . Although it is difficult, albeit tempting at this time, to propose a relationship between these observations, our results suggest that heparin alters the structure of ECGF by inducing it to assume a conformation with increased affinity for its receptor. Likewise, it is also possible that the receptor requires a heparin-ECGF complex for an ideal fit. These concepts may explain the structural interaction between ECGF and heparin (15) , the potentiation of ECGF biological activity by heparin (18) , the induction of epitope exposure on ECGF by heparin to monoclonal antibodies, and the restoration of biologically inactive ECGF by heparin-Sepharose. It is of considerable interest to note that heparin also interacts structurally with PDGF (28), insulinlike growth factor I (29), and FGF (30) . Although the heparin preparations used in these studies are extremely heterogeneous, we conclude that heparin, a fragment thereof, or some other molecular moiety occupies a binding domain or pocket within the native form of the polypeptide. Thus we suggest that ECGF, which may be delivered to the endothelial cell during the complex cascade of the neovascularization phenomenon by an endocrine, paracrine, or autocrine route (1) , interacts with and is potentiated by heparin, possibly derived from mast cells.
